



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

9<sup>th</sup> April, 2024

Corporate Relationship Department  
M/s. BSE Limited  
Dalal Street, Fort  
Mumbai 400 001.

The Manager - Listing  
M/s. National Stock Exchange of India Ltd  
"Exchange Plaza", Bandra – Kurla Complex  
Bandra (E) Mumbai 400 051

**Scrip Code: 524816**

**Scrip Code: NATCOPHARM**

Dear Sir/Madam,

Sub: Update on USFDA inspection at Natco's manufacturing facility in Kothur, Telangana

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to our intimation dated 19th October 2023 on the routine current Good Manufacturing Practices (cGMP) inspection at our Kothur (Pharma Division) manufacturing facility.

We wish to inform you that the Company has received a Warning Letter dated 8<sup>th</sup> April, 2024 from the United States Food and Drug Administration (USFDA). The Company does not believe that the Warning Letter will have an impact on disruption of supplies or existing revenues from this facility. It may cause delay/withholding of pending product approvals from this site.

The Company will respond to the Warning Letter within the stipulated timelines and work closely with the USFDA to address the concerns in a holistic and timely manner to ensure sustained compliance. The Company also remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally.

This is for your information and records.

Yours faithfully,  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer